$0.95
-0.02 (-2.27%)
Open$0.96
Previous Close$0.98
Day High$0.97
Day Low$0.90
52W High$270.00
52W Low—
Volume—
Avg Volume1.09M
Market Cap3.60M
P/E Ratio—
EPS$-219.70
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+282.5% upside
Current
$0.95
$0.95
Target
$3.65
$3.65
$2.40
$3.65 avg
$4.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 160.53M | 335.8K | 347.3K |
| Net Income | -2,762,681,282 | 43.0K | 52.4K |
| Profit Margin | -1,721.0% | 12.8% | 15.1% |
| EBITDA | -4,611,441,417 | 73.2K | 78.8K |
| Free Cash Flow | — | 45.7K | 64.8K |
| Rev Growth | — | +0.6% | +12.6% |
| Debt/Equity | — | 0.59 | 0.52 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |